DNA (RECOMBINANT ADENO-ASSOCIATED VIRUS AAVS3-FLT180A VECTOR HUMAN BLOOD-COAGULATION FACTOR IX PADUA-SPECIFYING)
Hemophilia B
Spur Therapeuticsgene_therapyPhase 1/2Dormant
CC
45/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 81/ 100
Competitive context
33 Active assets in the Hemophilia B cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Eptacog Alfa AryoGen Pharmed Co. | Phase 4 | A |
Factor Ix CSL Behring | Phase 4 | A |
Benefix Pfizer | Phase 4 | A |
Nonacog Beta Pegol Novo Nordisk A/S | Phase 3 | A |
Factor Ix CSL Behring | Phase 4 | BBB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →